The Relative Strength (RS) Rating for KalVista Pharmaceuticals entered a new percentile Friday, with an increase from 80 to 83.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an RS Rating of at least 80 in the early stages of their moves.
While KalVista Pharmaceuticals is not near a proper buy zone right now, see if it goes on to form and break out of a proper consolidation.
KalVista Pharmaceuticals showed 0% earnings growth in the latest quarterly report. Sales increased 0%.
The company earns the No. 257 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
